Loading...
Amphastar Q1 2025 Earnings Report
Amphastar Pharmaceuticals reported its financial results for the first quarter ended March 31, 2025.
Key Takeaways
Amphastar Pharmaceuticals reported net revenues of $170.5 million for the first quarter of 2025, a slight decrease from the previous year, with GAAP net income of $25.3 million and adjusted non-GAAP net income of $36.9 million. The company highlighted strong growth in BAQSIMI® and Primatene MIST® sales, alongside progress in its biosimilar pipeline.
Net revenues for Q1 2025 were $170.5 million.
GAAP net income for Q1 2025 was $25.3 million, or $0.51 per share.
Adjusted non-GAAP net income for Q1 2025 was $36.9 million, or $0.74 per share.
BAQSIMI® sales significantly increased by 177% due to assumed full distribution responsibilities.
Revenue by Segment
Forward Guidance
Amphastar Pharmaceuticals is confident in its portfolio's potential, driven by BAQSIMI® and Primatene MIST® growth, and a promising pipeline of biosimilars and proprietary products. The company is strategically managing resources for efficient operations and remains committed to sustainable growth and maximizing shareholder value.
Positive Outlook
- Confidence in the potential of the portfolio, particularly with the growth of BAQSIMI® and Primatene MIST®.
- Promising pipeline of biosimilars and proprietary products.
- FDA's acceptance of AMP-004 insulin biosimilar application marks a significant milestone.
- Strategic management of resources to ensure efficient operations.
- Firm commitment to achieving long-term goals of delivering sustainable growth and maximizing shareholder value.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...